NRF2 and cancer: the good, the bad and the importance of context
Open accessThe DOI matches its Crossref record; 119 of the 120 references it cites were found in a registry or an index.
Abstract
Many studies of chemopreventive drugs have suggested that their beneficial effects on suppression of carcinogenesis and many other chronic diseases are mediated through activation of the transcription factor NFE2-related factor 2 (NRF2). More recently, genetic analyses of human tumours have indicated that NRF2 may conversely be oncogenic and cause resistance to chemotherapy. It is therefore controversial whether the activation, or alternatively the inhibition, of NRF2 is a useful strategy for the prevention or treatment of cancer. This Opinion article aims to rationalize these conflicting perspectives by critiquing the context dependence of NRF2 functions and the experimental methods behind these conflicting data.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“NRF2 is mutationally activated in 10–30% of different solid tumors including liver, lung, stomach, colon and other cancers and mutations typically disrupt the interaction between NRF2 and its E3 ligase KEAP1 (Kelch Like ECH Associated Protein 1) directly or by impeding KEAP1 co-factors CUL3 (Cullin 3) and CAND1 (Cullin Associated and Neddylation Dissociated 1) [2,5,6,7,8].”
From NRF2 Activation Confers Resistance to eIF4A Inhibitors in Cancer Therapy (2021) · cites this paper as [5]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“NRF2 is mutationally activated in 10–30% of different solid tumors including liver, lung, stomach, colon and other cancers and mutations typically disrupt the interaction between NRF2 and its E3 ligase KEAP1 (Kelch Like ECH Associated Protein 1) directly or by impeding KEAP1 co-factors CUL3 (Cullin 3) and CAND1 (Cullin Associated and Neddylation Dissociated 1) [2,5,6,7,8].”
From NRF2 Activation Confers Resistance to eIF4A Inhibitors in Cancer Therapy (2021) · cites this paper as [5]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“NRF2 is activated and overexpressed in cancer to promote cancer cell survival; the cellular antioxidant system is largely regulated by NRF2 and its associated genes.30”
From Reactive Oxygen Species in Cancer: Current Findings and Future Directions (2021) · cites this paper as [30]
In the citing paper
“Furthermore, increased ROS levels facilitate the activation of HIF1α and NRF2 transcription factors, thus promoting transcriptional programs that further contribute to tumorigenesis (Bertout et al., 2008; Sporn and Liby, 2012).”
From The emerging hallmarks of cancer metabolism (2016) · cites this paper as Sporn and Liby, 2012
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
3 retracted
Niture, S. K., Jain, A. K., & Jaiswal, A. K. (2009) · Journal of Cell Science · doi:10.1242/jcs.058537 · Cited by 192
RetractedPhosphorylation and Dephosphorylation of Tyrosine 141 Regulate Stability and Degradation of INrf2
Jain, A. K., Mahajan, S., & Jaiswal, A. K. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m709854200 · Cited by 49
RetractedHsp90 Interaction with INrf2(Keap1) Mediates Stress-induced Nrf2 Activation
Niture, S. K., & Jaiswal, A. K. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.175802 · Cited by 41
RetractedTargeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach?
Trachootham, D., Alexandre, J., & Huang, P. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2803 · Cited by 5,452
Itoh, K., Chiba, T., Takahashi, S., Ishii, T., Igarashi, K., Katoh, Y., Oyake, T., Hayashi, N., Satoh, K., Hatayama, I., et al. (1997) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1997.6943 · Cited by 3,999
The Consensus Coding Sequences of Human Breast and Colorectal Cancers
Sjöblom, T., Jones, S., Wood, L. D., Parsons, D. W., Lin, J., Barber, T. D., Mandelker, D., Leary, R. J., Ptak, J., Silliman, N., et al. (2006) · Science · doi:10.1126/science.1133427 · Cited by 3,169
Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis
DeNicola, G. M., Karreth, F. A., Humpton, T. J., Gopinathan, A., Wei, C., Frese, K., Mangal, D., Yu, K. H., Yeo, C. J., Calhoun, E. S., et al. (2011) · Nature · doi:10.1038/nature10189 · Cited by 2,277
Protein tyrosine phosphatases: from genes, to function, to disease
Tonks, N. K. (2006) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2039 · Cited by 1,677
Cytostatic and apoptotic actions of TGF-β in homeostasis and cancer
Siegel, P. M., & Massagué, J. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1208 · Cited by 1,604
Molecular mechanisms of the Keap1-Nrf2 pathway in stress response and cancer evolution
Taguchi, K., Motohashi, H., & Yamamoto, M. (2011) · Genes to Cells · doi:10.1111/j.1365-2443.2010.01473.x · Cited by 1,478
Cited by
Items 801–900 of 1,000
Leung, C. K., Wang, Y., Deonarine, A., Tang, L., Prasse, S., & Choe, K. P. (2013) · Molecular and Cellular Biology · doi:10.1128/mcb.00245-13 · Cited by 8
“Interestingly, Nrf2 and Keap1 have been reported to have complex roles in cell proliferation and tumorigenesis in mammals and Drosophila, but the mechanisms are poorly understood (18, 19, 68, 69).”
BackgroundRetractedBrogi, S., Guarino, I., Flori, L., Sirous, H., & Calderone, V. (2023) · Computation · doi:10.3390/computation11120255 · Cited by 8
Tsouri, S., Tselo, E., Premetis, G. E., Furlan, V., Pantiora, P. D., Mavroidi, B., Matiadis, D., Pelecanou, M., Papageorgiou, A. C., Bren, U., et al. (2024) · Pharmaceuticals · doi:10.3390/ph17030365 · Cited by 8
“Moreover, nuclear factor erythroid 2-related factor 2 (NRF2) and glutathione transferases have also been studied as mediators of TMZ resistance in glioblastoma cells [53].”
BackgroundThe role of Nrf2 in immune cells and inflammatory autoimmune diseases: a comprehensive review
Xu, W., Yang, C., & Huang, A. (2024) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2024.2401518 · Cited by 11
“However, some other studies suggest that Nrf2 depends on the microenvironment to exert anti-inflammatory or pro-inflammatory effects [114].”
Feng, T., Xu, X., Wang, X., Tang, W., & Lu, Y. (2024) · Cell Death and Disease · doi:10.1038/s41419-024-07233-0 · Cited by 8
Dimethyl Fumarate vs. Monomethyl Fumarate: Unresolved Pharmacologic Issues
Kopincová, J., & Bernátová, I. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17121506 · Cited by 9
“…of fumarates across a broad spectrum of diseases should be tempered by awareness of the possible detrimental consequences of sustained constitutive NRF2 activation, which can promote tumorigenesis, tumour survival and metastasis, or end up in the induction of damaging reductive stress [66,151,152].”
Chen, J., Su, S., Pickar‐Oliver, A., Chiarella, A. M., Hahn, Q., Goldfarb, D., Cloer, E. W., Small, G. W., Sivashankar, S., Ramsden, D. A., et al. (2024) · Nucleic Acids Research · doi:10.1093/nar/gkae761 · Cited by 9
“Notably, the Keap1 / NRF2 signaling exerts context-dependent roles in tumorigenesis ( 69 ).”
BackgroundLubet, R. A., Townsend, R., Clapper, M. L., Juliana, M. M., Steele, V. E., McCormick, D. L., & Grubbs, C. J. (2016) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-15-0294 · Cited by 8
“Two particular classes of synthetic agents which exhibited strong ARE agonist activity are the dithiolthiones (24) and the triterpenoids (25).”
BackgroundVon Hippel-Lindau regulates interleukin-32β stability in ovarian cancer cells
Yong, H. J., Park, J. S., Jeong, A. L., Han, S., Lee, S., Ka, H. I., Sumiyasuren, B., Joo, H. J., So, S. J., Park, J. Y., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.19311 · Cited by 8
Мартинович, Г. Г., Martinovich, I. V., Вчерашняя, А. В., Зенков, Н. К., Брониславовна, М. Е., & Cherenkevich, S. N. (2020) · BIOPHYSICS · doi:10.1134/s000635092006010x · Cited by 9
Yang, Y. P., Wang, X., Zhang, J., Gu, H., Zhang, S., Sun, H., Liu, J., & Fan, R. (2022) · Aging · doi:10.18632/aging.204013 · Cited by 8
“Nrf2 is overexpressed in a variety of tumor cells and has been correlated with the occurrence and progression of many tumors, including advanced lung cancer, squamous cell carcinoma of the head and neck, liver cancer, esophageal squamous cell cancer, colon cancer, pancreatic cancer, gastric cancer, and gallbladder can…”
BackgroundKhramtsov, Y. V., Ulasov, A. V., Rosenkranz, A. A., Slastnikova, T. A., Lupanova, T. N., Georgiev, G. P., & Sobolev, A. S. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15020324 · Cited by 8
“In some, predominantly cancerous, cell lines, the proportion of free Nrf2 in the cytosol can be significant; in other words, the Nrf2 system in these cells is initially activated [41].”
BackgroundWu, Y., Lin, C., Lin, Y.-S., Su, W., & Chiu, W. C. (2018) · Cell Death Discovery · doi:10.1038/s41420-018-0098-6 · Cited by 12
Tian, F., Sun, S., Ge, Z., Ge, Y., Ge, X., Shi, Z., & Qian, X. (2024) · Journal of Nutrition · doi:10.1016/j.tjnut.2024.11.015 · Cited by 9
Olazábal-Morán, M., Pérez, E., Esteban-Arranz, A., & Garrido, A. (2025) · Biomolecules · doi:10.3390/biom15091316 · Cited by 8
“Experiments in animal models of lung cancer have been key to clarifying the differential function of NRF2. in the pathway [58].”
Lang, T., Xiao, P., Hua, S., Liang, X., & Yang, Y. (2025) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2025.09.054 · Cited by 7
Cirotti, C., Girolamo, C. D., Taddei, I., Contadini, C., Massacci, G., Sacco, F., Bufalo, D. D., Salvatori, I., Valle, C., & Barilà, D. (2025) · Cell Death and Differentiation · doi:10.1038/s41418-025-01542-3 · Cited by 7
Expression Patterns and Relevance of FN3K, Nrf2, and NQO1 in Breast Cancers
Beeraka, N. M., Zhang, J., Uthaiah, C. A., Anastasia, C. A., Liu, J., Vikram, P. R. H., Priyanka, M. K., Bannimath, N., Deka, R., Manogaran, P., et al. (2024) · Eurasian Journal of Medicine and Oncology · doi:10.14744/ejmo.2024.61033 · Cited by 7
“[15, 16] Nrf2 exhibits its significant implications in breast cancers, for instance, the nuclear Nrf2 levels could be considered as the prognostic factor in breast cancers.”
BackgroundZou, X., Wu, M., Tu, M., Tan, X., Long, Y., Xu, Y., & Li, M. (2024) · Journal of Receptors and Signal Transduction · doi:10.1080/10799893.2024.2341678 · Cited by 7
“…smad-dependent cascades or smad-independent signaling pathways to perform a variety of regulatory functions, which are involved in a variety of physiological and pathological processes including cell growth, differentiation, apoptosis and regulation of ECM synthesis and degradation [26, 27].”
BackgroundHirata, Y., Nakata, Y., Komatsu, H., Kudoh, Y., Takahashi, M., Taguchi, S., Noguchi, T., & Matsuzawa, A. (2024) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2024.05.009 · Cited by 7
Distinct Stress Regulators in the CRL Family: Emerging Roles of F‐Box Proteins
Hwang, J., Lauinger, L., & Kaiser, P. (2025) · BioEssays · doi:10.1002/bies.202400249 · Cited by 7
A novel small molecule that induces oxidative stress and selectively kills malignant cells
Šalipur, F. R., Reyes‐Reyes, E. M., Xu, B., Hammond, G. B., & Bates, P. J. (2013) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2013.12.002 · Cited by 8
Zhuang, S., Ding, N., Zhang, T., & Yu, X. (2022) · Current Protein and Peptide Science · doi:10.2174/1389203723666220823152239 · Cited by 8
Dhawan, A., Pifer, P. M., Sandulache, V. C., & Skinner, H. D. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1016217 · Cited by 8
“When cells undergo an oxidative stress, Keap1 is oxidized preventing Nrf2 ubiquitination which results in Nrf2 accumulation (67).”
BackgroundKeap1/Nrf2 impairing revised: are we missing the single nucleotide polymorphisms?
Muscarella, L. A., & Fazio, V. M. (2016) · Journal of Thoracic Disease · doi:10.21037/jtd.2016.12.85 · Cited by 7
“De novo synthetized Nrf2 translocates then into the nucleus and binds the antioxidant response elements (ARE) to the gene promoters of downstream cytoprotective factors, such as Phase II detoxifying enzymes, drug transporters, antiapoptotic proteins and proteasomes (2).”
BackgroundLee, J., Zhong, X., Lee, J.-Y., Surh, Y., & Na, H. (2019) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2019.108162 · Cited by 7
Wang, Y., Lin, S., Jiang, P., Song, Y., Zhao, Y., & Yu-jian, Z. (2021) · BioMed Research International · doi:10.1155/2021/6685493 · Cited by 7
“Upregulation of the levels of NO and endogenous antioxidant enzymes like SOD, catalase, and glutathione peroxidase can lead to ROS detoxi fi cation [43] and interrupt the ROS-in fl ammatory cycle, thus relieving oxidative damage and in fl ammation.”
BackgroundNukui, A., Narimatsu, T., Kambara, T., Abe, H., Sakamoto, S., Yoshida, K., & Kamai, T. (2018) · BMC Cancer · doi:10.1186/s12885-018-4427-1 · Cited by 7
“There have been reports about somatic mutations of Keap-1 and Nrf2 in many human cancers [16].”
Deng, Z., Jing, L., Ma, J., Jin, Y. N., & Yu, Y. V. (2024) · Aging · doi:10.18632/aging.205881 · Cited by 7
Ajuwon, O. R., Biteghe, F. A. N., Ndong, J. D. L. C., Davids, L. M., Ajiboye, B. O., Brai, B. I. C., Bamisaye, F. A., Falode, J. A., Odoh, I. M., Adegbite, K., et al. (2024) · OncoTargets and Therapy · doi:10.2147/ott.s457749 · Cited by 9
“90 The anti-cancer properties of synthetic and naturally-occurring chemopreventive substances, which are known inducers of Nrf2, are well reported.”
BackgroundYou, M., Tian, M., Song, Z., Liu, Z., Yang, B., & Zhang, S. (2024) · Nano Letters · doi:10.1021/acs.nanolett.3c03609 · Cited by 7
Hypoxia in Uterine Fibroids: Role in Pathobiology and Therapeutic Opportunities
Olson, S. L., Akbar, R. J., Gorniak, A., Fuhr, L. I., & Borahay, M. A. (2024) · Oxygen · doi:10.3390/oxygen4020013 · Cited by 10
“NRF2 is an anti-inflammatory transcription factor that regulates multiple pathways involved in cells’ response to oxidant signaling and damage [62].”
BackgroundMhaidly, N., Barake, N., Trelcat, A., Journé, F., Saussez, S., & Descamps, G. (2024) · Cancers · doi:10.3390/cancers16152739 · Cited by 7
“Our study demonstrated that bufalin reduces levels of NRF2, a transcription factor critical for antioxidant responses in cancer cells [56].”
BackgroundEvaluation of Nrf2, Keap1 and Apoptotic Pathway Genes Expression in Acute Myeloid Leukemia Patients.
Jalali, A., Mahmoudi, S., Harchegani, A. L., Asl, J. M., & Ahmadzadeh, A. (2021) · Iranian journal of pharmaceutical research · doi:10.22037/ijpr.2019.14907.12738 · Cited by 8
Huyan, T., Li, M., Chen, W., Zhou, X., Pei, D., Shang, P., & Wu, C. (2022) · Acta Astronautica · doi:10.1016/j.actaastro.2022.05.012 · Cited by 6
Vasco, V. R. L. (2023) · OBM Geriatrics · doi:10.21926/obm.geriatr.2302234 · Cited by 6
A detailed insight into macrophages' role in shaping lung carcinogenesis
Aktar, T., Modak, S., Majumder, D., & Maiti, D. (2024) · Life Sciences · doi:10.1016/j.lfs.2024.122896 · Cited by 6
Generation of non-standard macrocyclic peptides specifically binding TSC-22 homologous gene-1
Tran, S. T. P., Hipolito, C. J., Suzuki, H., Xie, R., Tuyen, H. D. K., ten Dijke, P., Terasaka, N., Goto, Y., Suga, H., & Kato, M. (2019) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2019.06.035 · Cited by 6
Sun, W.-C., Lin, C.-L., Lee, T., Chang, C., Ong, A.-Z., Yeh, Y.-H., Yu, C., Chen, G.-W., Hsieh, Y., & Wang, S. (2023) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2023.09.027 · Cited by 8
Dietary Carotenoids for Reduction of Cancer Risk
Lorenzo, J. M., & Munekata, P. E. S. (2016) · Studies in natural products chemistry · doi:10.1016/b978-0-444-63932-5.00006-1 · Cited by 6
Alimohammadi, M., Kahkesh, S., Cho, W. C. S., Farahani, N., Khoozani, M. F., Zare, A., Nejadheidari, A., Farani, M. R., Parizi, A. K., Asgharzadeh, F., et al. (2025) · APOPTOSIS · doi:10.1007/s10495-025-02127-8 · Cited by 7
Zakić, T., Jevtic, J., Vukobratovic, M., Djuric, S., Golić, I., Korać, A., Pekovic‐Vaughan, V., Janković, A., & Korać, B. (2025) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2025.07.027 · Cited by 7
Verdina, A., & D’Orazi, G. (2025) · Frontiers in Bioscience-Landmark · doi:10.31083/fbl39800 · Cited by 6
“NRF2 activation is a key mechanism for many chemo-preventive agents, helping to prevent tumorigenesis, although an excessive NRF2 activation may protect tumor cells from radiotherapy, reducing treatment efficacy [138].”
ERM Inhibition Confers Ferroptosis Resistance through ROS‐Induced NRF2 Signaling
Qiao, M., Zhou, L., Zhou, M., (219603), Y. F., Mai, H., Cao, L., Xu, K., Sang, Y., Chen, M., Huang, J., et al. (2026) · Advanced Science · doi:10.1002/advs.202513310 · Cited by 9
“All p values were calculated using a one-way or two-way analysis of variance (ANOVA). in the promoters of a wide range of anti-oxidant genes [ 67–70 ].”
Harada, H., Nie, Y., Araki, I., Soeno, T., Chuman, M., Washio, M., Sakuraya, M., Ushiku, H., Niihara, M., Hosoda, K., et al. (2021) · PLoS ONE · doi:10.1371/journal.pone.0260303 · Cited by 5
Shi, Z., Zhang, Y., Wang, X., Tang, J., Kang, Y., Hu, J., Li, L., Yang, B., Chen, S., Xiao, Q., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c01687 · Cited by 6
Sujitha, S., & Venkatalakshmi, P. (2021) · International Journal of Life Science and Pharma Research · doi:10.22376/ijpbs/lpr.2021.11.3.l1-11 · Cited by 17
Regulation of Nrf2 and Nrf2-related proteins by ganoderma lucidum ın hepatocellular carcinoma
Aslaminabad, R., Rahimianshahreza, N., Hosseini, S. A., Armağan, G., Khan, A. K., Özbolat, G., Ahmed, O. S., Azar, A. M., Adili, A., Dağcı, T., et al. (2022) · Molecular Biology Reports · doi:10.1007/s11033-022-07862-8 · Cited by 5
“Thus, there is an increasing need to establish a boundary between the positive and negative effects of Nrf2 on cancer and define a basis for rational targeted therapies for Nrf2 [13].”
BackgroundRole of autophagy in liver diseases
Morishita, H., & Komatsu, M. (2022) · Current Opinion in Physiology · doi:10.1016/j.cophys.2022.100594 · Cited by 6
The Anti-psoriatic Effect of Gallic Acid is Associated with the Suppression of Keratin 6 and Nrf2
Zhang, J., Qiu, H. X., Cao, X., & Han, L. (2023) · Letters in Drug Design & Discovery · doi:10.2174/1570180820666230314103222 · Cited by 5
Identification of prognostic and therapeutic biomarkers in type 2 papillary renal cell carcinoma
Wang, Y., Tian, X., Zhu, S., Xu, W., Anwaier, A., Su, J., Gan, H., Qu, Y., Zhao, J., Zhang, H., et al. (2023) · World Journal of Surgical Oncology · doi:10.1186/s12957-022-02836-3 · Cited by 5
“Currently, researchers are interested in the NRF2–ARE pathway, and novel strategies targeting this pathway have recently been developed [60, 61].”
BackgroundThe BRD4 Inhibitor I-BET-762 Reduces HO-1 Expression in Macrophages and the Pancreas of Mice
Leal, A. S., & Liby, K. T. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25189985 · Cited by 5
“HO-1 expression is partially regulated by NRF2 translocation to the nucleus and the consequent activation of downstream effectors [79].”
BackgroundSelf-citationAn unexpected alliance between stress responses to drive oncogenesis
Keenan, M. M., Ding, C. C., & Chi, J. (2014) · Breast Cancer Research · doi:10.1186/s13058-014-0471-1 · Cited by 5
“Similarly, various oxidative stresses promote the nuclear translocation of NRF2 to induce a set of genes that enhances oxidative-stress tolerance.”
BackgroundInfluentialLabgaa, I., Torrecilla, S., Martinez-Quetglas, I., & Sia, D. (2017) · Digestive Disease Interventions · doi:10.1055/s-0037-1603577 · Cited by 6
Soozangar, N., Sadeghi, M. R., Jeddi, F., Samadi, N., Hejazi, M. S., Azad, M., Shirmohamadi, M., & Somi, M. H. (2019) · Gazzetta Medica Italiana Archivio per le Scienze Mediche · doi:10.23736/s0393-3660.18.03799-3 · Cited by 5
Dionne, G., Calder, M. D., Betts, D. H., Rafea, B. A., & Watson, A. J. (2022) · Gene Expression Patterns · doi:10.1016/j.gep.2022.119281 · Cited by 5
Jeong, G., Oh, J., & Kim, J. (2019) · Journal of Medicinal Food · doi:10.1089/jmf.2018.4290 · Cited by 5
“3,4 Although p53 is a tumor suppressor and guardian of the genome, its mutation leads to loss of wild-type p53 activity, which is frequently found in many different tumor types. p53 and Nrf2 co-regulate each other both positively and negatively.”
Nrf2 Mutation/Activation Is Dispensable for the Development of Chemically Induced Mouse HCC
Mattu, S., Zavattari, P., Kowalik, M. A., Serra, M., Sulas, P., Pal, R. R., Puliga, E., Sutti, S., Foglia, B., Parola, M., et al. (2021) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2021.08.011 · Cited by 5
Adverse Outcome Pathway on Cyp2E1 activation leading to liver cancer
Webster, A. F., Lambert, I. B., & Yauk, C. L. (2021) · OECD series on adverse outcome pathways · doi:10.1787/56e9bbf0-en · Cited by 12
Eskandari, N., Delisi, D., Saatloo, M. V., Keceli, G., Pinheiro, N., Eblen, S. T., Paolocci, N., & Gentile, S. (2025) · Redox Biology · doi:10.1016/j.redox.2025.103942 · Cited by 5
“We selected HCT116 cells based on several key advantages: they are a well-characterized model of colorectal cancer with wild-type KEAP1 and NRF2, enabling the accurate interrogation of NRF2 regulatory dynamics [35].”
Yu, T., Yuanyuan, L. I., Zhu, J., Sun, Y., Li, Z., Liang, L., Zhu, Y., Dong, T., & Nie, F. (2026) · Chemical Engineering Journal · doi:10.1016/j.cej.2026.172706 · Cited by 5
Advances on the Role of Ferroptosis in Ionizing Radiation Response
Wang, F., Dai, Q., Xu, L., Gan, L., Shi, Y., Yang, M., & Yang, S. (2023) · Current Pharmaceutical Biotechnology · doi:10.2174/1389201024666230823091144 · Cited by 5
Insight into Nrf2: a bibliometric and visual analysis from 2000 to 2022
Ma, Y., Wang, Z., & Hu, Y. (2023) · Frontiers in Genetics · doi:10.3389/fgene.2023.1266680 · Cited by 5
“For instance, it enables cancer cells to become more resistant, avoiding apoptosis and senescence, while enhancing resistance to chemotherapy and radiation therapy (Sporn and Liby, 2012; Jaramillo and Zhang, 2013; Kansanen et al., 2013; Menegon et al., 2016).”
BackgroundFord, H. R., & Bionaz, M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25084264 · Cited by 4
“Much of the work regarding NRF2 has been conducted concerning its role in cancer, where it is often found to be constitutively activated, providing tumors with enhanced resistance to chemotherapeutics [9].”
BackgroundNRF2 protects lung epithelial cells from wood smoke particle toxicity
Lacher, S. E., Schumann, T., Peters, R., Migliaccio, C. T., Holian, A., & Slattery, M. G. (2024) · Advances in Redox Research · doi:10.1016/j.arres.2024.100115 · Cited by 4
1,4‐Dioxane Induces Epithelial‐Mesenchymal Transition and Carcinogenesis in an Nrf2‐Dependent Manner
Wang, Z., Thakur, C., Bi, Z., Qiu, Y., Zhang, W., Ji, H., Venkatesan, A. K., Cherukuri, S., Liu, K. J., Haley, J. D., et al. (2025) · Journal of Extracellular Vesicles · doi:10.1002/jev2.70072 · Cited by 5
“Given the oncogenic property of Nrf2 suggested by numerous studies (Sporn and Liby 2012), we monitored surrogate markers for tumour initiation, including anchorage-independent colony formation assay in soft agar, plate clonogenic growth, migration and invasion in WT and Nrf2 KO cells following…”
Phenolic Compounds Role in Rat Immunity Changes that Caused by Entamoeba Histolytica
Shahad Abbas Ali Al-Attar1, A. A. A. (2020) · Medico-Legal Update · doi:10.37506/mlu.v20i2.1156 · Cited by 4
“They also inhibit multiple enzymes responsible of ROS generation [25].”
BackgroundCastaño, S. C. G., Jiménez-González, F. J., Veloza, L. A., & Arias, J. C. (2020) · F1000Research · doi:10.12688/f1000research.26901.3 · Cited by 4
Kamai, T., Murakami, S., Arai, K., Nishihara, D., Uematsu, T., Ishida, K., & Kijima, T. (2022) · BMC Cancer · doi:10.1186/s12885-022-09415-5 · Cited by 6
“In addition, research recently showed that constitutive activation of Nrf2 promotes metabolic activity that supports cell proliferation and that increased expression of Nrf2 in tumors is associated with a poor prognosis [21, 22].”
BackgroundUnderstanding the Role of NRF2 Signalling in Cancer
Basalingappa, K. M., Singh, P. G., Gopenath, T. S., Ramesh Bharadwaj, M. N., & Ilangovan, R. (2022) · Current Protein and Peptide Science · doi:10.2174/1389203723666220914120325 · Cited by 4
Inflammation and Lung Cancer: The Relationship to Chronic Obstructive Pulmonary Disease
Houghton, A. M., & Shapiro, S. D. (2015) · Springer eBooks · doi:10.1007/978-1-4939-2724-1_1 · Cited by 4
Signaling Pathways of Anticancer Plants: Action and Reaction
Ahmad, B., Naikoo, M. I., Jaleel, H., Shabbir, A., Rehman, F., Sadiq, Y., & Khan, M. M. A. (2017) · Springer eBooks · doi:10.1007/978-981-10-8216-0_11 · Cited by 4
Han, L., Qiu, Y., He, L., Gao, C., Zhou, N., Fu, X., Xu, J., Lin, L., Wang, H., Biswal, S., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-65506-4 · Cited by 4
de Klerk, D. J., de Keijzer, M. J., Franchi, L. P., Tian, J., Gureev, M., Ge, Y., Mesquita, B. S., Saelman, G., herteryck, I. V., Dias, L. M., et al. (2025) · Biochemical Pharmacology · doi:10.1016/j.bcp.2025.117620 · Cited by 6
Chen, T., Liang, J., Liu, W., Zhou, F., Qiu, C., Peng, Y., & Zhou, X. (2026) · Analytica Chimica Acta · doi:10.1016/j.aca.2026.345120 · Cited by 4
Jiang, X., Yang, J., Zhang, Y., Zhang, Y., Ouyang, Z., Zhao, C., Lin, L., Yang, H., & Li, X. (2026) · Pharmaceuticals · doi:10.3390/ph19020251 · Cited by 5
Lu, M., Yang, Z., Xin, Y., Zhang, Y., Jiang, S., Zhu, J., You, Q., Zhao, Z., & Jiang, Z. (2026) · Journal of Advanced Research · doi:10.1016/j.jare.2026.05.030 · Cited by 4
The role of precision medicine for the treatment of metastatic renal cell carcinoma
Ciccarese, C., Nunno, V. D., Montironi, R., Fiorentino, M., Brunelli, M., Tortora, G., Ardizzoni, A., & Massari, F. (2016) · Expert Review of Precision Medicine and Drug Development · doi:10.1080/23808993.2016.1214057 · Cited by 3
“CDKN2A-alterated tumors are mainly type 2 pRCC, with a significantly lower rate of OS (in a univariate analysis) than those without CDKN2A-altererations Principal alterations driving loss of CDKN24 are focal loss of 9p21 or mutations or promoter hypermethylation of the CDKN2A gene Chromatin-modifying genes (BAP1, SETD…”
BackgroundYoo, O.-K., Lee, Y. S., Do, K.-H., & Keum, Y. (2017) · Journal of Life Science · doi:10.5352/jls.2017.27.3.310 · Cited by 3
“and translocates into the nucleus, thereby resulting in the binding of NRF2 to the anti-oxidant-response element (ARE), a nucleotide motif sequence that exist in 5’-upstream region of phase II cytoprotective genes [13].”
BackgroundMolecular Mechanisms of Nrf2 in Inflammation: Interactions Between Nrf2 and Inflammatory Mediators
Wang, R., & Pérez, V. (2020) · Progress in inflammation research · doi:10.1007/978-3-030-44599-7_1 · Cited by 6
Dragnev, K. H., Lubet, R. A., Miller, M. S., Sei, S., Fox, J. T., & You, M. (2023) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-23-0027 · Cited by 4
Involvement and Therapeutic Implication of JAK-STAT Pathway in Cancer
Rehman, A., Khan, N. A., Rashid, G., Tamanna, S., Jindal, R., Seth, N., Bashir, B., Mushtaq, G., Salman, M., & Parveen, S. (2025) · Springer eBooks · doi:10.1007/978-981-96-2763-9_8 · Cited by 5
Nrf2 – Two Faces of Antioxidant System Regulation
Pastorek, M., Müller, P., & Vojtěšek, B. (2015) · Klinicka onkologie · doi:10.14735/amko20152s26 · Cited by 4
Overexpressed somatic alleles are enriched in functional elements in Breast Cancer
Restrepo, P., Movassagh, M., Alomran, N., Miller, C., Li, M., Trenkov, C., Manchev, Y. T., Bahl, S., Warnken, S., Spurr, L. F., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-08416-w · Cited by 3
Oxidative Stress in the Tumor Immune Microenvironment
Wang, Y., Hu, Y., Jiang, Y., & Zhou, S. (2021) · Springer eBooks · doi:10.1007/978-981-16-0522-2_2 · Cited by 3
Baenke, F., Dhomen, N. S., Gottlieb, E., & Marais, R. (2019) · Springer eBooks · doi:10.1007/978-1-4614-7322-0_28-2 · Cited by 3
Zakić, T., Stojanovic, S., Janković, A., Korać, A., Pekovic‐Vaughan, V., & Korać, B. (2022) · BioFactors · doi:10.1002/biof.1931 · Cited by 4
Identification of NRF2 Activation as a Prognostic Biomarker in T-Cell Acute Lymphoblastic Leukaemia
Villa‐Morales, M., Pérez-Gómez, L., Pérez-Gómez, E., López‐Nieva, P., Fernández‐Navarro, P., & Santos, J. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241210350 · Cited by 4
“In the early stages, transient activation of the antioxidative role of NRF2 seems to be relevant for avoiding premalignant tumorigenesis, DNA damage, and initial cancer mutations [11,12].”
BackgroundImpact of Nrf2 overexpression on cholangiocarcinoma treatment and clinical prognosis
Lee, H., Min, S. K., Cho, M.-S., & Lee, H. K. (2023) · Korean Journal of Clinical Oncology · doi:10.14216/kjco.23004 · Cited by 3
“However, cancer cells can hijack Nrf2 activity to support their malignant growth, making Nrf2 a potential therapeutic target [9-13].”
BackgroundFiletti, M., Occhipinti, M. A., Cirillo, A., Scirocchi, F., Ugolini, A., Giusti, R., Lombardi, P., Daniele, G., Botticelli, A., Russo, G. L., et al. (2024) · Cancers · doi:10.3390/cancers16233955 · Cited by 3
The Role of Nrf2 in Glioma: Therapeutic Targeting Strategies
Harifi-Mood, M. S., Alemzadeh, E., Barati, D., Dehghani, A. H., Siroosi, F. Z., Aschner, M., Samini, F., Samarghandian, S., & Farkhondeh, T. (2025) · Current Cancer Drug Targets · doi:10.2174/0115680096331620250119111525 · Cited by 4
Irabor, F., Ebohon, O., Ibukun, O., Ayevbuomwan, M., & Omoregie, E. S. (2021) · Scientific African · doi:10.1016/j.sciaf.2021.e00950 · Cited by 3
Senolytic Phytocompounds in Redox Signaling
Thirumurugan, K. (2021) · Healthy ageing and longevity · doi:10.1007/978-3-030-84965-8_12 · Cited by 3
Neurochemical Aspects of Oxidative and Nitrosative Stress
Farooqui, A. A. (2014) · Springer eBooks · doi:10.1007/978-3-319-04111-7_6 · Cited by 3
Aksenov, V., Boreham, D. R., & Rollo, C. D. (2014) · Mutagenesis · doi:10.1093/mutage/geu002 · Cited by 3
Hereditary Renal Cell Carcinoma
Baba, M., Schmidt, L. S., & Linehan, W. M. (2017) · Springer eBooks · doi:10.1007/978-4-431-55531-5_2 · Cited by 4
Kamai, T., Murakami, S., Arai, K., Ishida, K., & Kijima, T. (2022) · Cancer Science · doi:10.1111/cas.15379 · Cited by 4
A metagene of NRF2 expression is a prognostic biomarker in all stage colorectal cancerPreprint
O'Cathail, S. M., Wu, C., Lewis, A., Holmes, C. C., Hawkins, M., & Maughan, T. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/690974 · Cited by 3
“However more recent evidence shows that some tumours acquire constitutive activation of the pathway which allow it to function in an ‘oncogene’ like fashion, promoting cell survival, resisting radiation, chemotherapeutics and dysregulating metabolism [12,13].”
BackgroundThe caloric restriction fallacy, rodent diet aids and the tumor suppression theory of agingPreprint
Wolf, A. M. (2021) · OSF Preprints (OSF Preprints) · doi:10.31219/osf.io/a2689 · Cited by 2
Manfreda, L., Rruga, F., Zanolli, A., Marzullo, B. P., Vettore, L. A., Canton, M., Canton, M., Marchioro, C., Rampazzo, E., Mariotto, E., et al. (2026) · Redox Biology · doi:10.1016/j.redox.2026.104380 · Cited by 2
Metadata
- Authors
- Sporn, M. B., & Liby, K. T.
- Affiliations
- Dartmouth College (US)
- Corresponding author
- Sporn, Michael B.
- Liby, Karen T.
- ORCID
- Liby, Karen T.
- Venue
- Nature Reviews Cancer
- Published
- 2012-07-19
- Volume
- 12
- Issue
- 8
- Pages
- 564-571
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- PMC
- PMC3836441
- OpenAlex
- W2030749349
- Cited by
- 1,067
- References
- 120
- Citations by year
- 2026: 36 · 2025: 48 · 2024: 70 · 2023: 72 · 2022: 88 · 2021: 90 · 2020: 97 · 2019: 93 · 2018: 112 · 2017: 88 · 2016: 93 · 2015: 62 · 2014: 57 · 2013: 50 · 2012: 11
- FWCI
- 5.31
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature reviews. Cancer (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (R01CA078814, P30CA023108)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics, phytochemicals, and oxidative stress
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Bioactive Compounds and Antitumor Agents
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Glutathione Transferases and Polymorphisms
- Keywords
- Nrf2, chemoprevention, carcinogenesis, chemoresistance, transcription factor activation
- MeSH terms
- Animals, Cell Transformation, Neoplastic, Humans, Neoplasms, Anticarcinogenic Agents, Tumor Suppressor Proteins, NF-E2-Related Factor 2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.